Shockwave Medical Inc (OQ:SWAV)
Business Focus: Medical Equipment
Rain as of March 01, 2023
For the latest outlook, get the company report
You may also be interested in
Insider Filings
Latest 10 SEC Form 4 filings for SWAV*US within the last 6 months
See all filings within the past 6 months
Read full article
Read full article
See more news stories
See all valuations
Loading...
Company News
Mar 14, 2023 08:00 ET
Shockwave Medical Announces U.S. Launch of New Peripheral IVL Catheter
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat severely calcified cardiovascular disease, today announced the full U.S. commercial availability of the Shockwave L6 Peripheral IVL...
Feb 16, 2023 16:02 ET
Shockwave Medical Reports Fourth Quarter and Full Year 2022 Financial Results
Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year...
Valuation Ratios
Industry
Sector
Beta
0.97
--
--
Price to Sales - TTM
16.16
6.32
3.59
Price to Book - most recent quarter
15.37
2.31
1.88
Price to Cash Flow per share - TTM
35.83
24.27
13.32
Price to Free Cash Flow per share - TTM
85.45
71.14
27.88
Business Summary
| Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
Shockwave Medical, Inc. is a medical device company. The Company is focused on development and commercialization of products intended to transform the way calcified cardiovascular disease is treated. It provides care for the treatment of calcified cardiovascular disease through its differentiated local delivery of sonic pressure waves, intravascular lithotripsy (IVL). Its Shockwave M5 IVL catheter and Shockwave M5+ IVL catheter are five-emitter catheters for use in its IVL System in medium-diameter vessels for the treatment of peripheral artery disease (PAD). Its Shockwave S4 IVL catheter is a four-emitter catheter for use in its IVL System in small-diameter vessels for the treatment of PAD. Its Shockwave L6 IVL catheter is a six-emitter catheter for use in its IVL System in large diameter vessels for the treatment of PAD. Its Shockwave C2 IVL catheter and Shockwave C2+ IVL catheter are two-emitter catheters for use in its IVL System for the treatment of coronary artery disease (CAD).
See business summary
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
US Quotes Data provided by IEX. Additional price data powered by Twelve Data. Company fundamental sourced from © Refinitiv. Click for restrictions. © Refinitiv. All rights reserved. Republication or redistribution of Refinitiv, including by framing or similar means, is prohibited without the prior written consent of Refinitiv. Refinitiv is not liable for any errors or delays in Refinitiv content, or for any actions taken in reliance on such content.
Interactive technical study charts by TradingView. Copyright © 2023 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.